{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:43:08Z","timestamp":1777938188053,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary hyperoxaluria (PH) is a rare inherited disorder characterized by excessive oxalate accumulation in blood and urine due to defects in glyoxylate metabolism, leading to significant clinical consequences. As genetic and phenotypic heterogeneity contribute to the morbidity of PH, this study examined the phenotypes and genotypes of PH among confirmed pediatric patients (&lt;\u200918 years) diagnosed with PH at a tertiary care center in Saudi Arabia between 2014 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-one patients from 14 families, including 10 boys (47.6%) and 11 girls (52.4%), were included. Six families had more than one affected child. The median age at diagnosis was 36 months (interquartile range\u2009=\u20096\u201384). All but one patient had PH type 1 [due to alanine\u2013glyoxylate aminotransferase gene variant (\n                      <jats:italic>AGXT<\/jats:italic>\n                      )], with the remaining patient having PH type 2 [associated with glyoxylate and hydroxypyruvate reductase gene (GRHPR)]. The most frequent variant in the\n                      <jats:italic>AGXT<\/jats:italic>\n                      gene was NM_000030.3: c.33dup (p.Lys12GlnfsTer156), which was detected in 38.1% of patients. High parental consanguinity (90.5%) and positive family history (81%) were notable. The major clinical manifestations were kidney stones (71.4%), nephrocalcinosis (47.6%), failure to thrive (38.1%), stage V chronic kidney disease (42.9%), and hematuria (33.3%). All patients received conservative management, in addition to liver transplantation in eight patients and combined liver\u2013kidney transplantation in two patients. The mortality rate was 14.3% (3\/21).\n                      <jats:italic>AGXT<\/jats:italic>\n                      variants such as NM_000030.3:c.481G\u2009&gt;\u2009A(p.(Gly161Ser) and NM_000030.3: c.346G\u2009&gt;\u2009A (p.(Gly116Arg) displayed potential trends with worse renal prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PH type 1 is the predominant form of hyperoxaluria among Saudi patients. High consanguinity might contribute to its disease burden. Early diagnosis and intervention are critical for improving outcomes. Recently approved RNA interference-based therapies offer promising outcomes, potentially reducing the need for organ transplantation in patients with PH type 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trail number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04082-8","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:44:30Z","timestamp":1761659070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Primary hyperoxaluria: insights into its clinical presentation, genetic mutations, and transplantation outcomes in a pediatric population in a tertiary care center"],"prefix":"10.1186","volume":"20","author":[{"given":"Bayan","family":"Sayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Alhuthil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sermin","family":"Saadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turki","family":"Al-Shareef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Alhassoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essam","family":"Al-Sabban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"4082_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369:649\u201358.","journal-title":"N Engl J Med"},{"key":"4082_CR2","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol. 2015;26:2559\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"4082_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1620\/tjem.246.233","volume":"246","author":"X Li","year":"2018","unstructured":"Li X, Gu J, Yang Y, Li J, Li Y. A putative mutation hotspot of the AGXT gene associated with primary hyperoxaluria type 1 in the Chinese population. Tohoku J Exp Med. 2018;246:233\u201341.","journal-title":"Tohoku J Exp Med"},{"key":"4082_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.ekir.2023.09.012","volume":"8","author":"PS Vali","year":"2023","unstructured":"Vali PS, H\u00f6ppe B. Is genotype the major outcome parameter of kidney failure in patients with primary hyperoxaluria type 1? Kidney Int Rep. 2023;8:2187\u201390.","journal-title":"Kidney Int Rep"},{"key":"4082_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00240-023-01494-8","volume":"51","author":"J Wu","year":"2023","unstructured":"Wu J, Song J, He Y, Zhong C, Yang Q, Li Q, et al. Case series and literature review of primary hyperoxaluria type 1 in Chinese patients. Urolithiasis. 2023;51:23.","journal-title":"Urolithiasis"},{"key":"4082_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12882-017-0612-8","volume":"18","author":"I M\u2019barek","year":"2017","unstructured":"M\u2019barek I, Mdimeg S, Moussa A, Zellama D, Kaarout H, Abdelmoula J, et al. Unusual clinical outcome of primary hyperoxaluria type 1 in Tunisian patients carrying 33_34InsC mutation. BMC Nephrol. 2017;18:195.","journal-title":"BMC Nephrol"},{"key":"4082_CR7","first-page":"18","volume":"27","author":"M Amiryan","year":"2023","unstructured":"Amiryan M, Leviashvili ZG, Savenkova ND. Primary hyperoxaluria I, II, III types in children (review of literature). Nephrology. 2023;27:18\u201330.","journal-title":"Nephrology"},{"key":"4082_CR8","doi-asserted-by":"publisher","first-page":"1124745","DOI":"10.3389\/fgene.2023.1124745","volume":"14","author":"Q Xin","year":"2023","unstructured":"Xin Q, Dong Y, Guo W, Zhao X, Liu Z, Shi X, et al. Four novel variants identified in primary hyperoxaluria and genotypic and phenotypic analysis in 21 Chinese patients. Front Genet. 2023;14:1124745.","journal-title":"Front Genet"},{"key":"4082_CR9","first-page":"856","volume":"49","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Li Q, Liang S. Infant primary hyperoxaluria type 1. Chin J Pediatr. 2024;49:856\u201362.","journal-title":"Chin J Pediatr"},{"key":"4082_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.ekir.2024.01.063","volume":"9","author":"T d\u2019Izarny-Gargas","year":"2024","unstructured":"d\u2019Izarny-Gargas T, Dang J, Gr\u00fcnenwald A, Mechref Z, Besson FL, Ferlicot S, et al. Bone marrow oxalosis. Kidney Int Rep. 2024;9:1139\u201341.","journal-title":"Kidney Int Rep"},{"key":"4082_CR11","first-page":"e53888","volume":"16","author":"AM Khayat","year":"2024","unstructured":"Khayat AM, Alshareef BG, Alharbi SF, AlZahrani MM, Alshangity BA, Tashkandi NF. Consanguineous marriage and its association with genetic disorders in Saudi Arabia: a review. Cureus. 2024;16:e53888.","journal-title":"Cureus"},{"key":"4082_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00467-022-05784-y","volume":"38","author":"M Alfadhel","year":"2023","unstructured":"Alfadhel M, Umair M, Alghamdi MA, Al Fakeeh K, Al Qahtani AT, Farahat A, et al. Clinical and molecular characterization of a large primary hyperoxaluria cohort from Saudi Arabia: a retrospective study. Pediatr Nephrol. 2023;38:1801\u201310.","journal-title":"Pediatr Nephrol"},{"key":"4082_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5144\/0256-4947.1999.4","volume":"19","author":"SA Sanjad","year":"1999","unstructured":"Sanjad SA, Al-Abbad A, Al-Sabban E. Primary hyperoxaluria type I: an underestimated cause of nephrocalcinosis and chronic renal failure in Saudi Arabian children. Ann Saudi Med. 1999;19:4\u20137.","journal-title":"Ann Saudi Med"},{"key":"4082_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00345-018-2563-5","volume":"37","author":"L He","year":"2019","unstructured":"He L, Xu G, Fang X, Lin H, Xu M, Yu Y, et al. Identification of 8 novel gene variants in primary hyperoxaluria in 21 Chinese children with urinary stones. World J Urol. 2019;37:1713\u201321.","journal-title":"World J Urol"},{"key":"4082_CR15","first-page":"15886","volume":"12","author":"NA Soliman","year":"2022","unstructured":"Soliman NA, Elmonem MA, Abdelrahman SM, Nabhan MM, Fahmy YA, Cogal AG, et al. Clinical and molecular characterization of primary hyperoxaluria in Egypt. Dent Sci Rep. 2022;12:15886.","journal-title":"Dent Sci Rep"},{"key":"4082_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"4082_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrneph.2012.113","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8:467\u201375.","journal-title":"Nat Rev Nephrol"},{"key":"4082_CR18","doi-asserted-by":"publisher","first-page":"sfae099","DOI":"10.1093\/ckj\/sfae099","volume":"17","author":"R Pszczolinski","year":"2024","unstructured":"Pszczolinski R, Acquaviva C, Berrahal I, Biebuyck N, Burtey S, Clabault K, et al. Primary hyperoxaluria in adults and children: a nationwide cohort highlights a persistent diagnostic delay. Clin Kidney J. 2024;17:sfae099.","journal-title":"Clin Kidney J"},{"key":"4082_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ekir.2024.10.006","volume":"10","author":"B Hoppe","year":"2025","unstructured":"Hoppe B, Martin-Higueras C, Borghese L, Kaspar S, Reusch B, Beck BB, et al. Effective newborn screening for type 1 and 3 primary hyperoxaluria. Kidney Int Rep. 2025;10:177\u201383.","journal-title":"Kidney Int Rep"},{"key":"4082_CR20","unstructured":"National Center for Biotechnology Information (NCBI). ClinVar: NM_000030.3(AGXT):c.481G\u2009>\u2009A (p.Gly161Ser) [Internet]. Bethesda (MD): National Library of Medicine (US); [updated 2025; cited 2025 Jul 27]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/204105\/"},{"issue":"10","key":"4082_CR21","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.ekir.2023.07.025","volume":"8","author":"EL Metry","year":"2023","unstructured":"Metry EL, Garrelfs SF, Deesker LJ, Acquaviva C, D\u2019ambrosio V, Bacchetta J, Beck BB, Cochat P, Collard L, Hogan J, Ferraro PM. Determinants of kidney failure in primary hyperoxaluria type 1: findings of the European hyperoxaluria consortium. Kidney Int Rep. 2023;8(10):2029\u201342.","journal-title":"Kidney Int Rep"},{"key":"4082_CR22","unstructured":"National Center for Biotechnology Information (NCBI). ClinVar: NM_000030.3(AGXT):c.346G\u2009>\u2009A (p.Gly116Arg) [Internet]. Bethesda (MD): National Library of Medicine (US); [updated 2025; cited 2025 Jul 27]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/189021\/"},{"key":"4082_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/gtmb.2015.0136","volume":"19","author":"L Boualla","year":"2015","unstructured":"Boualla L, Tajir M, Oulahiane N, Lyahyai J, Laarabi FZ, Chafai Elalaoui S, et al. AGXT gene mutations and prevalence of primary hyperoxaluria type 1 in Moroccan population. Genet Test Mol Biomarkers. 2015;19:623\u20138.","journal-title":"Genet Test Mol Biomarkers"},{"key":"4082_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00240-020-01201-x","volume":"49","author":"F Zhao","year":"2021","unstructured":"Zhao F, Li J, Tang L, Li C, Wang W, Ning C. Characteristics of the genotype and phenotype in Chinese primary hyperoxaluria type 1 populations. Urolithiasis. 2021;49:17\u201325.","journal-title":"Urolithiasis"},{"key":"4082_CR25","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/ajmg.a.35495","volume":"158A","author":"R Tammachote","year":"2012","unstructured":"Tammachote R, Kingsuwannapong N, Tongkobpetch S, Srichomthong C, Yeetong P, Kingwatanakul P, et al. Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2. Am J Med Genet A. 2012;158A:2124\u201330.","journal-title":"Am J Med Genet A"},{"key":"4082_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000086357","volume":"25","author":"Y Frishberg","year":"2005","unstructured":"Frishberg Y, Rinat C, Shalata A, Khatib I, Feinstein S, Becker-Cohen R, et al. Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. Am J Nephrol. 2005;25:269\u201375.","journal-title":"Am J Nephrol"},{"key":"4082_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00467-023-06200-9","volume":"39","author":"S Krishnasamy","year":"2024","unstructured":"Krishnasamy S, Deepthi B, Kamath N, Iyengar A, Thomas CC, Uthup S, et al. Clinical characteristics, genetic profile and short-term outcomes of children with primary hyperoxaluria type 2: a nationwide experience. Pediatr Nephrol. 2024;39:1093\u2013104.","journal-title":"Pediatr Nephrol"},{"key":"4082_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ki.2009.435","volume":"77","author":"J Harambat","year":"2010","unstructured":"Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 2010;77:443\u20139.","journal-title":"Kidney Int"},{"key":"4082_CR29","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves first drug to treat rare metabolic disorder. Silver Spring, MD: FDA. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-rare-metabolic-disorder. Accessed 10 Jul 2024."},{"key":"4082_CR30","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00467-025-06665-w","volume":"40","author":"S Saffe","year":"2025","unstructured":"Saffe S, Doerry K, B\u00fcscher AK, Hansen M, Rohmann M, Kanzelmeyer N, et al. Variable treatment response to Lumasiran in pediatric patients with primary hyperoxaluria type 1. Pediatr Nephrol. 2025;40:1929\u201337.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"4082_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ki.2009.237","volume":"76","author":"S Fargue","year":"2009","unstructured":"Fargue S, Harambat J, Gagnadoux MF, Tsimaratos M, Janssen F, Llanas B, et al. Effect of Conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int. 2009;76(7):767\u201373.","journal-title":"Kidney Int"},{"key":"4082_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","volume":"19","author":"JW Groothoff","year":"2023","unstructured":"Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and oxaleurope. Nat Rev Nephrol. 2023;19:194\u2013211.","journal-title":"Nat Rev Nephrol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04082-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:03:16Z","timestamp":1761699796000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04082-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4082"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04082-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics committee of the King Faisal Specialist Hospital and Research Centre (reference number: 2231334). Written consent was obtained from the parents and\/or caregivers of the patients for the genetic study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"546"}}